Tesla faces declining global sales, safety concerns, and scrutiny over CEO Elon Musk's controversies, as competition intensifies and the Cybertruck struggles with pricing challenges.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Tesla faces declining global sales, safety concerns, and scrutiny over CEO Elon Musk's controversies, as competition intensifies and the Cybertruck struggles with pricing challenges.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.